Ocugen Appoints Rita Johnson-Greene, A Veteran Leader With 20+ Years Of Experience As Chief Financial Officer,

Ocugen, Inc., a biotechnology company focused on gene therapies for blindness-related diseases, has appointed Rita Johnson-Greene as its new Chief Financial Officer. She brings more than two decades of experience across healthcare, finance, and commercial operations.

“Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this year.”

Before joining Ocugen, Johnson-Greene served as Chief Operating Officer at the Alliance for Regenerative Medicine, where she oversaw operations and finance and helped drive the organization’s global expansion to support the development and access of cell and gene therapies. Earlier, she was Vice President of Sales and Qualified Treatment Centers at Genetix Biotherapeutics, formerly bluebird bio, where she built U.S. commercial teams ahead of the launches of the ZYNTEGLO and SKYSONA gene therapies.

“I am excited to join Ocugen and believe in the potential of the Company’s novel modifier gene therapy platform to address unmet medical needs that still exist for major blindness diseases,” said Mrs. Johnson-Greene. “Having been in the cell and gene therapy space for many years, I understand the unique business needs required to operate efficiently and drive future success.”

Her previous leadership roles include positions at Spark Therapeutics, where she supported the launch of LUXTURNA, and at AstraZeneca, where she worked across finance, sales, and commercial operations in both North and South America. She began her professional career in strategic consulting with Accenture’s strategy practice.

Johnson-Greene holds an MBA in Finance and Strategic Management from the Wharton School of the University of Pennsylvania and a bachelor’s degree in Electrical and Computer Engineering from Drexel University. She also serves on Drexel University’s Biomed Dean’s Executive Advisory Council and regularly lectures graduate students in biomedical programs.